# A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

> **NCT06177912** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 882 (actual)

## Conditions studied

- Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT06177912
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-18
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-02-26
- **Target enrollment:** 882 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177912, "A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06177912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*